These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9427720)

  • 1. Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha.
    Yanagisawa K; Yamauchi H; Kaneko M; Kohno H; Hasegawa H; Fujita S
    Blood; 1998 Jan; 91(2):641-8. PubMed ID: 9427720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis.
    Selleri C; Maciejewski JP; Pane F; Luciano L; Raiola AM; Mostarda I; Salvatore F; Rotoli B
    Blood; 1998 Aug; 92(3):981-9. PubMed ID: 9680367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
    Tang LJ; Chen HC; Peng XH
    Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
    Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
    Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Different sensitivity of two chronic myeloid leukemia cell lines to interferon-alpha].
    Li XM; Chen HC; Liu XF; Wu YH; Cao YF
    Ai Zheng; 2003 Oct; 22(10):1047-52. PubMed ID: 14558948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of therapeutic effects of low-dose versus high-dose interferon alpha-2b treatment on chronic myelocytic leukemia: a prospective randomized study].
    Du JW; Zhu P; Tian D; Dong ZR; Yang SL; Li SB; Tang YH; Liu H; Cen XN; Zhang Y; Zhu Q; Zhu YL; Yang Y; Wang DX; Wang Z; Cui H; Ma YG; Chen WM; Liu FQ; Ma J; Wang JW; Shen T; Da WM
    Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1305-9. PubMed ID: 16029627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.
    Pane F; Mostarda I; Selleri C; Salzano R; Raiola AM; Luciano L; Saglio G; Rotoli B; Salvatore F
    Blood; 1999 Oct; 94(7):2200-7. PubMed ID: 10498589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
    Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
    Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
    Sick C; Schultheis B; Pasternak G; Kottke I; Hörner S; Heissig B; Hehlmann R
    Ann Hematol; 2001 Jan; 80(1):9-16. PubMed ID: 11233781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts.
    Andersson BS; Collins VP; Kurzrock R; Larkin DW; Childs C; Ost A; Cork A; Trujillo JM; Freireich EJ; Siciliano MJ
    Leukemia; 1995 Dec; 9(12):2100-8. PubMed ID: 8609723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
    Drexler HG; MacLeod RA; Uphoff CC
    Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
    Zhang JH; He YL; Zhu R; Du W; Xiao JH
    Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-α in CML cell line, KT-1 cells.
    Nishiyama-Fujita Y; Shimizu T; Sagawa M; Uchida H; Kizaki M
    Leuk Res; 2013 Sep; 37(9):1150-5. PubMed ID: 23759247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
    Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
    Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis.
    Grebenová D; Kuzelová K; Fuchs O; Halada P; Havlícek V; Marinov I; Hrkal Z
    Blood Cells Mol Dis; 2004; 32(1):262-9. PubMed ID: 14757443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells.
    Sakai I; Takeuchi K; Yamauchi H; Narumi H; Fujita S
    Blood; 2002 Oct; 100(8):2926-31. PubMed ID: 12351404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
    Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
    J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.